Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
LITMUS Imaging Study
NCT05479721 · View on ClinicalTrials.gov ↗
Study Summary
The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD). It aims to evaluate the diagnostic performance of imaging biomarkers (ultrasound elastography and magnetic resonance biomarkers) against NAFLD histological scores in a cross-sectional analysis and the natural history of NAFLD in a longitudinal study.
Conditions Studied
Study Locations (18)
Other
- Helsinki University Hospital — Helsinki
- Le Centre de Recherche Clinique (CRC) du CHU d'Angers — Angers
- Institut ICAN - Institute of Cardiometabolism And Nutrition Hôpital de la Pitié Salpêtrière — Paris
- UNIVERSITÄTSMEDIZIN der Johannes Gutenberg Universität Mainz — Mainz
- Universitätsklinikums Würzburg — Würzburg
- Laiko General Hospital of Athens — Athens
- Università di Palermo — Palermo
- Department of Medical Sciences University of Torino — Torino
- Vall d'Hebron University Hospital — Barcelona
- Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital — Seville
- HU Clínico de Valladolid — Valladolid
- Linköping University Hospital — Linköping
- Inselspital, University Hospital — Bern
- Addenbrookes Hospital — Cambridge
- The Newcastle Upon Tyne Hospitals Nhs Foundation Trust — Newcastle upon Tyne
- Queens Medical Centre — Nottingham
- Oxford University Hospitals NHS Foundation Trust — Oxford
Texas
- Pinnacle Clinical Research — San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2019-09-04 |
| Est. Completion | 2025-10-31 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05479721
The ClinicalTrials.gov registry entry for NCT05479721 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oxford, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05479721 reports 18 study locations spanning 2 distinct geographic areas — top geographies include Other, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05479721 about?
NCT05479721 is a clinical study titled "LITMUS Imaging Study". The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD). It aims to evaluate the diagnostic performance of imaging biomarkers (ultrasound elastography and magnetic resonance biomarkers) against...
What is the current status of trial NCT05479721?
This trial is currently active not recruiting. The enrollment target is 450 participants. The study started on 2019-09-04. Estimated completion is 2025-10-31.
What conditions does trial NCT05479721 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis, NAFLD, NASH, Fibrosis, Liver, Steatosis of Liver. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT05479721?
This trial is sponsored by University of Oxford, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05479721 being conducted?
This trial has 18 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.